stockrow
Friday 6 November 2026
Export TXG’s income statement to Excel — free account
10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
58.35
0.29
+0.50%
Follow TXG
Alert me
10x Genomics (TXG) Net income
10x Genomics's net income for fiscal 2025 was −$43.5M, compared with −$182.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$67.1M. Over the past ten years it has ranged from −$542.7M (fiscal 2020) to −$18.8M (fiscal 2017); the current reading is higher than 78% of that period. 10x Genomics ranks 129th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$43.5M | — |
| FY2024 | −$182.6M | — |
| FY2023 | −$255.1M | — |
| FY2022 | −$166.0M | — |
| FY2021 | −$58.2M | — |
| FY2020 | −$542.7M | — |
| FY2019 | −$31.3M | — |
| FY2018 | −$112.5M | — |
| FY2017 | −$18.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$19.4M | — |
| Jun 2026 | −$17.9M | — |
| Mar 2026 | −$13.5M | — |
| Dec 2025 | −$16.3M | — |
| 29 more quarters | Free account |
Against its own ten years
Low −$542.7M
High −$18.8M
Ten-year median
−$112.5M
Current reading's percentile
78
Net income against peers
| Company | Net income |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $616.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $616.6M |
| GMED Globus Medical, Inc. compare | $557.6M |
| PODD Insulet Corporation compare | $428.8M |
| PEN Penumbra, Inc. compare | $157.0M |
| HAE Haemonetics Corporation compare | $103.9M |
| TXG 10x Genomics | −$75.1M |
| BRKR Bruker Corporation compare | −$115.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TXG
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement